Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: -6.70%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
Amicus Therapeutics reported strong financial and operational performance with significant revenue growth driven by successful product launches and strategic market expansion. Despite currency exchange rate exposures and regulatory complexities, the company's outlook remains positive with targets for continued revenue growth and improved profitability.Company Guidance
During the Amicus Therapeutics Full Year 2024 Financial Results Conference Call, the company reported a significant financial performance. Total revenue reached $528 million, reflecting a 32% year-over-year growth or 33% on a constant currency basis. Galafold, one of their key products, generated $458 million in revenue, marking an 18% increase from the previous year. There are now over 2,700 patients with Fabry disease using Galafold, with the treated market doubling to 12,000 globally. The company projects Galafold revenue growth of 10% to 15% in 2025. Pombiliti and Opfolda, therapies for Pompe disease, also saw robust growth with $70 million in revenue and a projected growth of 65% to 85% for 2025. Amicus achieved over $0.5 billion in global revenue and managed operating expenses within their guidance range, achieving non-GAAP profitability for 2024. For 2025, they aim for a total revenue growth of 17% to 24% and positive GAAP net income in the second half.Record Revenue Growth
Amicus reported total revenue of $528 million for 2024, representing a 32% increase year-over-year, exceeding guidance of 30% to 32% growth at constant exchange rates.
Strong Galafold Performance
Galafold achieved $458 million in revenue, with 18% growth year-on-year, or 19% at constant exchange rates. It has over 65% of the global market share of treated Fabry patients with amenable mutations.
Successful Launch of Pombiliti and Opfolda
Pombiliti and Opfolda generated over $70 million in revenue in 2024 with strong global demand and successful launches in multiple countries. Expected revenue growth for 2025 is projected at 65% to 85%.
Strategic Market Expansion
Plans to launch Pombiliti and Opfolda in up to 10 new countries in 2025, with approvals anticipated in Canada and Japan and recent approval in Australia.
Positive Financial Outlook
Amicus achieved non-GAAP profitability in 2024, with a non-GAAP net income of $74 million, and is targeting positive GAAP net income in the second half of 2025.
---
FOLD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FOLD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $9.85 | $9.56 | -2.94% |
| Nov 06, 2024 | $11.74 | $11.24 | -4.26% |
| Aug 08, 2024 | $10.00 | $11.32 | +13.20% |
| May 09, 2024 | $10.14 | $9.48 | -6.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amicus Therapeutics (FOLD) report earnings?
Amicus Therapeutics (FOLD) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Amicus Therapeutics (FOLD) earnings time?
Amicus Therapeutics (FOLD) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FOLD EPS forecast?
FOLD EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---